Bristol-Myers Squibb
Executive Summary
William Comer, PhD, appointed to senior VP-strategic management of Bristol-Myers Squibb Pharmaceutical Group with responsibility for worldwide licensing, strategic product planning and commercial development. Prior to his new appointment, Comer was president of Bristol-Myers Pharmaceutical Research and the Bristol-Myers Squibb Licensing Group, not president of Bristol-Myers Pharmaceutical Research & Development as reported in the March 29 "The Pink Sheet" (T&G-9). His responsibilities included Bristol-Myers Research & Development Division, Oncogen, and Bristol-Myers Squibb licensing functions. Among those reporting to Comer was Stephen Carter, MD, president of Bristol-Myers Pharmaceutical Research & Development Division since last September. Carter now reports to new Bristol-Myers Squibb Research Institute President Edgar Haber, MD.
|
William Comer, PhD, appointed to senior VP-strategic management of
Bristol-Myers Squibb Pharmaceutical Group with responsibility for
worldwide licensing, strategic product planning and commercial
development. Prior to his new appointment, Comer was president of
Bristol-Myers Pharmaceutical Research and the Bristol-Myers Squibb
Licensing Group, not president of Bristol-Myers Pharmaceutical
Research & Development as reported in the March 29 "The Pink
Sheet" (T&G-9). His responsibilities included Bristol-Myers
Research & Development Division, Oncogen, and Bristol-Myers
Squibb licensing functions. Among those reporting to Comer was
Stephen Carter, MD, president of Bristol-Myers Pharmaceutical
Research & Development Division since last September. Carter
now reports to new Bristol-Myers Squibb Research Institute
President Edgar Haber, MD. |